Company file · ALNY
Alnylam
Royalty was Alnylam's fastest-growing product or service in FY2025, up 89.6%
Revenue rose 65.2% to $3.7B in FY2025, from $2.2B in FY2024. Net income was $314M, against a net loss of $278M a year earlier. Products was the largest product or service, at 80% of revenue.
Key facts
Alnylam (Nasdaq: ALNY) closed fiscal 2025 on Dec 31, 2025 with revenue of $3.7B, up 65.2% from a year before; net income came to $314M, compared with −$278M. Its newest quarterly report covers the three months to Sep 30, 2026: revenue of $1.5B, up 16.7% on the same stretch of the prior year, and net income of $2.2B. Broken down by product or service, Products led with 80% of fiscal 2025 revenue. Sources: 10-K for fiscal 2025 (filed Feb 12, 2026) and 10-Q for the quarter ended Sep 30, 2026 (filed Oct 29, 2026).
Source: 10-K FY2025, filed Feb 12, 2026
How it makes money
By product or service, FY2025
Source: 10-K FY2025, XBRL breakdown
By product or service in FY2025: Products (80%), Collaborations (15%) and Royalty (5%), as shares of total revenue. Total revenue was $3.7B.
Source: 10-K FY2025
Learn more: Revenue vs. net income · Gross, operating and net margin
What changed last quarter
Comparing Q3 2026 (Jul to Sep 2026) compared with Q3 2025 (Jul to Sep 2025)
Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.
Q3 2026Q3 2025
Company
Source: Alnylam 10-Q for the quarter ended Sep 30, 2026, filed Oct 29, 2026
By product or service
Source: Alnylam 10-Q for the quarter ended Sep 30, 2026, filed Oct 29, 2026
The bull case and the bear case
The bull case
- Revenue rose 65.2% in FY2025 to $3.7B, from $2.2B a year earlier. 10-K, FY2025
- Net income was $314M in FY2025, against a net loss of $278M in FY2024. 10-K, FY2025
- Operating cash flow rose 6405.1% in FY2025 to $524M. 10-K, FY2025
- Revenue in the quarter ended Sep 30, 2026 was $1.5B, up 16.7% on a year earlier. 10-Q, quarter ended Sep 30, 2026
The bear case
- Diluted shares rose 5.5% in FY2025, which spreads profit across more shares. 10-K, FY2025
- The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A
What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.
What the company does
Alnylam is in the biotechnology industry, part of the health care sector. The SEC files it under Pharmaceutical Preparations.
The full description of Alnylam's business is in Item 1 of its 10-K, linked below. This page shows its revenue by product or service.
Its fiscal year ends in December; the latest, FY2025, ended Dec 31, 2025.
Source: 10-K, Item 1 Business
Risks common in this industry
These are general risks for companies in the biotechnology industry. They are not a summary of Alnylam’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.
- RegulationApprovals, safety rules and government oversight shape what it can sell and how.
- Pricing and reimbursementPayers, insurers and governments influence what it can charge.
- CompetitionNew treatments, generics and rival products can take share.
- LitigationProduct liability and other legal claims can lead to costs.
- SupplyManufacturing and supplier problems can interrupt products.
Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)
Three years of key numbers
Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.
| US$ | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $1.8B | $2.2B | $3.7B |
| Net income | −$440M | −$278M | $314M |
| Operating cash flow | $104M | −$8M | $524M |
| Cash & equivalents (year end) | $813M | $966M | $1.7B |
| Diluted shares | 125M | 128M | 135M |
- Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
- Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
- Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
- Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
- Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.
Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator
Explainers for this page
- The cash flow statement
- Risk factors (Item 1A)
- Legal proceedings and loss contingencies
- Debt-to-equity ratio
- Return on equity (ROE)
- Finding filings on SEC EDGAR
- How ETF shares are created
Guides to terms this file uses, with real numbers from filings.
About these numbers
What we left out
- Total debt: the company's filing data doesn't carry a consistent debt total for the years shown, so it isn't shown.
Recent filings
| Form | Filed | Period |
|---|---|---|
| 10-Q | Oct 29, 2026 | Sep 30, 2026 |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 |
| DEF 14A | Apr 6, 2026 | May 20, 2026 |
| 10-K | Feb 12, 2026 | Dec 31, 2025 |
What's in this filing
The quotes below come from Item 1 (Business) of the Form 10-K Alnylam filed on Feb 12, 2026, its annual report for the fiscal year ended Dec 31, 2025.
The latest quarterly report in the table above is the Form 10-Q filed Oct 29, 2026 for the quarter ended Sep 30, 2026.
A 10-K has audited annual financial statements and the company's own description of its business and risks; a 10-Q has unaudited quarterly statements.
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi.
RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
Short excerpts quoted from the filing. The full document is on SEC.gov.
Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters
Common questions about Alnylam
How does Alnylam make money?
Fiscal 2025 revenue: $3.7B. By product or service in FY2025: Products (80%), Collaborations (15%) and Royalty (5%), as shares of total revenue. Total revenue was $3.7B. Source: 10-K for fiscal 2025, filed Feb 12, 2026.
What was Alnylam's revenue in fiscal 2025?
$3.7B, up 65.2% from fiscal 2024 ($2.2B). The year ended Dec 31, 2025; for fiscal 2023 the figure was $1.8B. Source: 10-K for fiscal 2025, filed Feb 12, 2026.
Is Alnylam profitable?
Net income was $314M in fiscal 2025 (compared with −$278M; fiscal 2024 was −$278M). That counts as a GAAP profit. The latest quarter, ended Sep 30, 2026: net income was $2.2B. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2025, filed Feb 12, 2026.
What did Alnylam report in its latest quarterly filing?
For the three months to Sep 30, 2026: revenue $1.5B (up 16.7% from $1.2B) and net income $2.2B (up 640.5% from $293M). Source: 10-Q for the quarter ended Sep 30, 2026, filed Oct 29, 2026.
What are the main risks Alnylam faces?
Alnylam's own risk factors are in Item 1A of its 10-K for fiscal 2025, filed Feb 12, 2026. Risks that are common among companies in the biotechnology industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.
Where do these Alnylam numbers come from?
The 10-K filed Feb 12, 2026 (fiscal 2025) and the 10-Q filed Oct 29, 2026 (quarter ended Sep 30, 2026), as published in the SEC's XBRL data. Click any number to open the filing it came from. Methodology explains how fiscal years and missing numbers are handled.
Tracked funds that report owning Alnylam
- Baillie Gifford: 5,492,469 shares, reported value $1.36B at Sep 30, 2026 (+125.1% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 9, 2026.
- Two Sigma Investments: 848,525 shares, reported value $209.4M at Sep 30, 2026 (−54.8% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 16, 2026.
- Millennium Management: 377,728 shares, reported value $93.2M at Sep 30, 2026 (+19.5% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 16, 2026.
- Citadel Advisors: 191,029 shares, reported value $57.5M at Jun 30, 2026 (+715.8% in shares since the filing for Mar 31, 2026). Form 13F filed Sep 2, 2026.
- Bridgewater Associates: 28,463 shares, reported value $7.0M at Sep 30, 2026 (−71.4% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 16, 2026.
- Maverick Capital: 907 shares, reported value $0.2M at Sep 30, 2026 (new in this filing). Form 13F filed Nov 16, 2026.
From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.
Disclosures
- Editor holdings in ALNY
- The editor holds no position in Alnylam (ALNY). As of Nov 11, 2026.
- Trading rule
- The editor does not buy or sell ALNY from 3 days before to 3 days after this page is published or substantively updated.
- Compensation
- Nobody paid for this page. No affiliate links on this page.
- Sources
- The company's SEC filings, linked next to each number or, for charts, in the source line under them.
- Last updated
- Nov 20, 2026
General education, the same for every reader. Not a recommendation to buy, sell or hold ALNY, and it doesn't consider your situation.
Compare with peers
| Company | Fiscal year | Revenue | Revenue growth | Net income |
|---|---|---|---|---|
| AlnylamALNY | FY2025 | $3.7B | +65.2% | $314M |
| AbbVieABBV | FY2025 | $61.2B | +8.6% | $4.2B |
| AmgenAMGN | FY2025 | $36.8B | +10.0% | $7.7B |
| GileadGILD | FY2025 | $29.4B | +2.4% | $8.5B |
| Vertex PharmaceuticalsVRTX | FY2025 | $12.0B | +8.9% | $4.0B |
Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.
More company files
- LLY Eli Lilly
- JNJ Johnson & Johnson
- MRK Merck
- TMO Thermo Fisher
- PFE Pfizer
- DHR Danaher
- BMY Bristol Myers Squibb
- HCA HCA Healthcare
- REGN Regeneron Pharmaceuticals
- MRNA Moderna
- VEEV Veeva Systems
- A Agilent Technologies
- WAT Waters
- IQV IQVIA
- ILMN Illumina
- BIIB Biogen
- MTD Mettler Toledo
- ZTS Zoetis
- INCY Incyte
- VTRS Viatris
- CRL Charles River Laboratories
- SOLV Solventum
- TECH Bio-Techne
- UHS Universal Health Services
- UTHR United Therapeutics
- THC Tenet Health
- MEDP Medpace
- AAPL Apple
- MSFT Microsoft
- NVDA Nvidia
New to filings? Learn has explainers built on real filings and Tools has calculators. Methodology & Disclosures covers where every number comes from.